JP2021152002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021152002A5 JP2021152002A5 JP2021052571A JP2021052571A JP2021152002A5 JP 2021152002 A5 JP2021152002 A5 JP 2021152002A5 JP 2021052571 A JP2021052571 A JP 2021052571A JP 2021052571 A JP2021052571 A JP 2021052571A JP 2021152002 A5 JP2021152002 A5 JP 2021152002A5
- Authority
- JP
- Japan
- Prior art keywords
- hour
- administration
- obinutuzumab
- pharmaceutical composition
- cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003347 obinutuzumab Drugs 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 238000001802 infusion Methods 0.000 description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574297P | 2017-10-19 | 2017-10-19 | |
| US62/574,297 | 2017-10-19 | ||
| JP2019508989A JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Division JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021152002A JP2021152002A (ja) | 2021-09-30 |
| JP2021152002A5 true JP2021152002A5 (enExample) | 2021-12-02 |
| JP7370357B2 JP7370357B2 (ja) | 2023-10-27 |
Family
ID=64362606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Active JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
| JP2021052571A Active JP7370357B2 (ja) | 2017-10-19 | 2021-03-26 | 医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Active JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12129304B2 (enExample) |
| EP (2) | EP3697818B1 (enExample) |
| JP (2) | JP6860652B2 (enExample) |
| KR (2) | KR102766089B1 (enExample) |
| CN (2) | CN120983618A (enExample) |
| AU (2) | AU2018303836B2 (enExample) |
| BR (1) | BR112020007731A2 (enExample) |
| CA (1) | CA3079374A1 (enExample) |
| ES (1) | ES3005784T3 (enExample) |
| IL (2) | IL321935A (enExample) |
| MX (2) | MX2020003418A (enExample) |
| PL (1) | PL3697818T3 (enExample) |
| TW (2) | TWI828593B (enExample) |
| WO (1) | WO2019017499A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003418A (es) * | 2017-10-19 | 2020-07-20 | Hoffmann La Roche | Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab. |
| US20240050562A1 (en) * | 2019-10-04 | 2024-02-15 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| JPWO2023042679A1 (enExample) | 2021-09-17 | 2023-03-23 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| SI3179992T1 (sl) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| US11149091B2 (en) * | 2015-12-09 | 2021-10-19 | Cedars-Sinai Medical Center | Methods for treating nephrotic syndrome |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| JP6881583B2 (ja) | 2017-07-21 | 2021-06-02 | 横浜ゴム株式会社 | 空気入りタイヤ |
| MX2020003418A (es) * | 2017-10-19 | 2020-07-20 | Hoffmann La Roche | Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab. |
-
2018
- 2018-10-19 MX MX2020003418A patent/MX2020003418A/es unknown
- 2018-10-19 CN CN202511095071.9A patent/CN120983618A/zh active Pending
- 2018-10-19 TW TW112120572A patent/TWI828593B/zh active
- 2018-10-19 KR KR1020207014191A patent/KR102766089B1/ko active Active
- 2018-10-19 KR KR1020247035575A patent/KR20240157135A/ko active Pending
- 2018-10-19 CN CN201880067120.XA patent/CN111212854A/zh not_active Withdrawn
- 2018-10-19 CA CA3079374A patent/CA3079374A1/en active Pending
- 2018-10-19 IL IL321935A patent/IL321935A/en unknown
- 2018-10-19 JP JP2019508989A patent/JP6860652B2/ja active Active
- 2018-10-19 US US16/756,057 patent/US12129304B2/en active Active
- 2018-10-19 EP EP18804720.3A patent/EP3697818B1/en active Active
- 2018-10-19 AU AU2018303836A patent/AU2018303836B2/en active Active
- 2018-10-19 EP EP24213649.7A patent/EP4520347A3/en active Pending
- 2018-10-19 PL PL18804720.3T patent/PL3697818T3/pl unknown
- 2018-10-19 BR BR112020007731-3A patent/BR112020007731A2/pt unknown
- 2018-10-19 ES ES18804720T patent/ES3005784T3/es active Active
- 2018-10-19 TW TW107137033A patent/TWI805630B/zh active
- 2018-10-19 WO PCT/JP2018/038924 patent/WO2019017499A2/en not_active Ceased
-
2020
- 2020-04-12 IL IL273909A patent/IL273909B2/en unknown
- 2020-07-13 MX MX2024009217A patent/MX2024009217A/es unknown
-
2021
- 2021-03-26 JP JP2021052571A patent/JP7370357B2/ja active Active
-
2024
- 2024-09-23 US US18/893,101 patent/US20250026847A1/en active Pending
-
2025
- 2025-07-15 AU AU2025205481A patent/AU2025205481A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012321110B2 (en) | Combination treatment | |
| JP2021152002A5 (enExample) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2017075183A5 (enExample) | ||
| JP6360438B2 (ja) | 癌の治療 | |
| JP2018507243A5 (enExample) | ||
| JP2019514858A5 (enExample) | ||
| JP2019514974A5 (enExample) | ||
| CN107872975A (zh) | 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合 | |
| Hansen et al. | Express subcutaneous IgG infusions: decreased time of delivery with maintained safety | |
| JP2019517549A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2024517194A (ja) | サイケデリック薬の用量を漸増する方法 | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2018531605A5 (enExample) | ||
| JP2021152002A (ja) | 医薬組成物 | |
| JP2023011549A5 (enExample) | ||
| Bevans et al. | Rituximab as an adjuvant rescue treatment for ocular cicatricial pemphigoid | |
| JP2017502058A5 (enExample) | ||
| Kim et al. | Helicobacter pylori eradication therapy in Korea | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| Kranke et al. | Management of postoperative nausea and vomiting (PONV) | |
| JP2005529152A5 (enExample) | ||
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 |